Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111748
Status:
COMPLETED
Last Update Posted:
2015-10-06
First Post:
2005-05-24
Brief Title:
UARK 2005-01 Study of Velcade Thalidomide and Dexamethasone VTD With or Without Adriamycin in RelapsedRefractory Patients
Sponsor:
University of Arkansas
Organization:
University of Arkansas
Study Overview
Official Title:
UARK 2005-01 A Phase III Study of Velcade Thalidomide and Dexamethasone VTD With or Without Adriamycin in RelapsedRefractory Patients
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main goal of this study is to evaluate the effectiveness of the combination of these drugs and whether they can be given safely together
Detailed Description:
In this study there will be two arms or groups One arm will receive Velcade thalidomide and dexamethasone VTD and the other arm will receive VTD with Adriamycin
This study has the following specific goal
To evaluate the efficacy and toxicity of two treatments in multiple myeloma patients relapsing after at least one course of high-dose treatment and an autologous stem cell transplant or after at least two lines of conventional chemotherapy
This study has the following specific goal
To evaluate the efficacy and toxicity of two treatments in multiple myeloma patients relapsing after at least one course of high-dose treatment and an autologous stem cell transplant or after at least two lines of conventional chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None